Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 8.01 (Other Events). Cash and cash equivalents totaled $107.1 million as of March 31, 2026.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Cash and cash equivalents totaled $107.1 million as of March 31, 2026
- Approximately $28.7 million raised through common-stock warrant exercises in April and May 2026
- Cash proceeds improve near-term funding capacity for SELLAS’s operations and clinical programs
- Common shares outstanding reached 196,632,574 as of June 2, 2026, signaling dilution for existing shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.